Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review

Miao, Jing; Gao, Peng; Li, Qian; He, Kuifeng; Zhang, Liwen; Wang, Junyan; Huang, Lingfei

doi:10.3390/ijms222011227

Cited by 11 publications

(4 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, nano drug delivery systems can improve nose-to-brain delivery by protecting encapsulated drugs from biological and chemical degradation and by transporting P-gp efflux proteins across extracellular spaces [11]. Several nano drug delivery systems with specific biochemical properties have been designed to achieve personalized and targeted therapy [12].…”

Section: Analysis Of Scientometric Resultsmentioning

confidence: 99%

A Review of Non-Invasive Drug Delivery through Respiratory Routes

Zhang

Bai

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

With rapid and non-invasive characteristics, the respiratory route of administration has drawn significant attention compared with the limitations of conventional routes. Respiratory delivery can bypass the physiological barrier to achieve local and systemic disease treatment. A scientometric analysis and review were used to analyze how respiratory delivery can contribute to local and systemic therapy. The literature data obtained from the Web of Science Core Collection database showed an increasing worldwide tendency toward respiratory delivery from 1998 to 2020. Keywords analysis suggested that nasal and pulmonary drug delivery are the leading research topics in respiratory delivery. Based on the results of scientometric analysis, the research hotspots mainly included therapy for central nervous systems (CNS) disorders (Parkinson’s disease, Alzheimer’s disease, depression, glioblastoma, and epilepsy), tracheal and bronchial or lung diseases (chronic obstructive pulmonary disease, asthma, acute lung injury or respiratory distress syndrome, lung cancer, and idiopathic pulmonary fibrosis), and systemic diseases (diabetes and COVID-19). The study of advanced preparations contained nano drug delivery systems of the respiratory route, drug delivery barriers investigation (blood-brain barrier, BBB), and chitosan-based biomaterials for respiratory delivery. These results provided researchers with future research directions related to respiratory delivery.

show abstract

Section: Analysis Of Scientometric Resultsmentioning

confidence: 99%

A Review of Non-Invasive Drug Delivery through Respiratory Routes

Zhang

Bai

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The understanding of the tissue and intracellular environments has enabled the utilization of receptor specific ligands in the design of the nanocarrier systems. 104 Several examples of targeted delivery to hepatocytes have been described 105 Receptor mediated-delivery with high affinity ligands may have advantages of specificity if the receptors are cell-specific. Any nonspecific uptake by scavenger receptors such as those present on Kupffer cells may decrease the efficiency of delievery.…”

Section: Discussionmentioning

confidence: 99%

Novel Approaches to Inhibition of HBsAg Expression from cccDNA and Chromosomal Integrants: A Review

Abdelwahed,

Heineman,

2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is a widely prevalent liver infection that can cause acute or chronic hepatitis. Although current treatment modalities are highly effective in the suppression of viral levels, they cannot eliminate the virus or achieve definitive cure. This is a consequence of the complex nature of HBV-host interactions. Major challenges to achieving sustained viral suppression include the presence of a high viral burden from the HBV DNA and hepatitis B surface antigen (HBsAg), the presence of reservoirs for HBV replication and antigen production, and the HBV-impaired innate and adaptive immune response of the host. Those therapeutic methods include cell entry inhibitors, HBsAg inhibitors, gene editing approaches, immune-targeting therapies and direct inhibitors of covalently closed circular DNA (cccDNA). Novel approaches that target these key mechanisms are now being studied in preclinical and clinical phases. In this review article, we provide a comprehensive review on mechanisms by which HBV escapes elimination from current treatments, and highlight new agents to achieve a definitive HBV cure.

show abstract

“…Other nanoparticle materials include ferritin nanoparticles. Ferro nanoparticle vaccine has been shown to eliminate the hepatitis B virus in mice, and many clinical trials are ongoing [ 78 , 79 ].…”

Section: Formulation and Delivery Of Mrna Vaccinesmentioning

confidence: 99%

Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses

Kutikuppala,

Kourampi,

Kanagala

et al. 2024

Medical Sciences

View full text Add to dashboard Cite

mRNA vaccines have emerged as an optimistic technological platform for vaccine innovation in this new scientific era. mRNA vaccines have dramatically altered the domain of vaccinology by offering a versatile and rapid approach to combating infectious diseases and virus-induced cancers. Clinical trials have demonstrated efficacy rates of 94–95% in preventing COVID-19, and mRNA vaccines have been increasingly recognized as a powerful vaccine platform. Although mRNA vaccines have played an essential role in the COVID-19 pandemic, they still have several limitations; their instability and degradation affect their storage, delivery, and over-all efficiency. mRNA is typically enclosed in a transport mechanism to facilitate its entry into the target cell because it is an unstable and negatively charged molecule. For instance, mRNA that is given using lipid-nanoparticle-based vaccine delivery systems (LNPs) solely enters cells through endocytosis, establishing an endosome without damaging the cell membrane. The COVID-19 pandemic has accelerated the development of mRNA vaccine platforms used to treat and prevent several infectious diseases. This technology has the potential to change the future course of the disease by providing a safe and effective way to combat infectious diseases and cancer. A single-stranded genetic sequence found in mRNA vaccines instructs host cells to produce proteins inside ribosomes to elicit immunological responses and prepare the immune system to fight infections or cancer cells. The potential applications of mRNA vaccine technology are vast and can lead to the development of a preferred vaccine pattern. As a result, a new generation of vaccinations has gradually gained popularity and access to the general population. To adapt the design of an antigen, and even combine sequences from different variations in response to new changes in the viral genome, mRNA vaccines may be used. Current mRNA vaccines provide adequate safety and protection, but the duration of that protection can only be determined if further clinical research is conducted.

show abstract

Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review

Cited by 11 publications

References 113 publications

A Review of Non-Invasive Drug Delivery through Respiratory Routes

A Review of Non-Invasive Drug Delivery through Respiratory Routes

Novel Approaches to Inhibition of HBsAg Expression from cccDNA and Chromosomal Integrants: A Review

Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses

Contact Info

Product

Resources

About